Triple Agonist

Triple Agonist

A triple agonist is a pharmacological agent engineered to activate three separate receptor pathways with a single molecule. In metabolic medicine, this term most commonly refers to molecules that target the three key gut-derived and pancreatic hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. Retatrutide (LY3437943) is the most advanced triple agonist in clinical development.

The rationale for triple agonism builds on the established success of single agonists (e.g., semaglutide targeting GLP-1 alone) and dual agonists (e.g., tirzepatide targeting GIP and GLP-1). Each additional receptor pathway is hypothesized to contribute distinct metabolic benefits: GLP-1 agonism drives appetite suppression and glycemic control, GIP agonism modulates fat tissue function and enhances satiety, and glucagon agonism increases energy expenditure and promotes hepatic lipid oxidation. Together, these three pathways may produce metabolic effects greater than the sum of their individual contributions.

Designing a single peptide that effectively activates all three receptors is a significant pharmaceutical engineering challenge. The native ligands for GIP, GLP-1, and glucagon receptors share some structural homology, as all three belong to the glucagon superfamily of peptides. Researchers at Eli Lilly leveraged this evolutionary relationship to construct retatrutide’s peptide backbone, incorporating specific amino acid modifications to achieve the desired balance of receptor activation potencies and to extend the molecule’s duration of action for once-weekly administration.

The clinical data from retatrutide’s Phase 2 program suggest that the triple agonist approach yields weight loss and metabolic improvements that exceed what has been reported for single or dual agonists, though direct head-to-head comparisons are needed to confirm these observations.